Arbutus Biopharma (ABUS) 10-Q 6 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	TEKMIRA PHARMACEUTICALS CORP
Document Type	10-Q
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		54,224,261
Amendment Flag	FALSE
Entity Central Index Key	1447028
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$232,276	$72,187
Short-term investments (note 2)		39,974
Accounts receivable	4,564	1,903
Accrued revenue	1,595	538
Investment tax credits receivable	79	86
Prepaid expenses and other assets	1,255	1,730
Total current assets	239,769	116,418
Property and equipment	11,925	12,959
Less accumulated depreciation	-10,147	-11,199
Property and equipment, net of accumulated depreciation	1,778	1,760
Intangible assets (note 3)	389,652
Goodwill (note 3)	155,865
Total assets	787,064	118,178
Current liabilities:
Accounts payable and accrued liabilities (note 5)	14,019	9,328
Deferred revenue (note 4)	5,233	5,779
Warrants (note 2)	5,623	5,099
Total current liabilities	24,875	20,206
Deferred revenue, net of current portion (note 4)	7,897	9,937
Contingent consideration (note 8)	4,736
Deferred tax liability (note 3)	155,865
Total liabilities	193,373	30,143
Stockholders’ equity:
Issued and outstanding: 54,095,921 (December 31, 2014 - 22,438,169)	814,441	290,004
Additional paid-in capital	28,590	26,208
Deficit	-217,853	-205,864
Accumulated other comprehensive loss	-31,487	-22,313
Total stockholders' equity	593,691	88,035
Total liabilities and stockholders' equity	$787,064	$118,178

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Common shares, shares issued	54,095,921	22,438,169
Common shares, shares outstanding	54,095,921	22,438,169
Common shares, no par value (in Dollars per share)
Common shares, authorized

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue (note 4)
Collaborations and contracts	$3,520,000	$3,689,000
Licensing fees, milestone and royalty payments	1,162,000	741,000
Total revenue	4,682,000	4,430,000
Expenses
Research, development, collaborations and contracts	10,557,000	8,204,000
General and administrative	2,716,000	2,050,000
Depreciation of property and equipment	120,000	134,000
Acquisition costs (note 3)	9,295,000
Total expenses	22,688,000	10,388,000
Loss from operations	-18,006,000	-5,958,000
Interest income	202,000	147,000
Foreign exchange gains	7,038,000	1,443,000
Increase in fair value of warrant liability (note 2)	-1,223,000	-13,616,000
Net loss	-11,989,000	-17,984,000
Basic and diluted (in Dollars per share)	($0.40)	($0.91)
Basic and diluted (in Shares)	30,208,136	19,801,428
Comprehensive loss
Cumulative translation adjustment	-9,174,000	-2,159,000
Comprehensive loss	($21,163,000)	($20,143,000)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (USD $)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Total
Balance, at Dec. 31, 2014	$290,004,000	$26,208,000	($205,864,000)	($22,313,000)	$88,035,000
Balance, shares (in Shares) at Dec. 31, 2014	22,438,169
Stock-based compensation		2,934,000			2,934,000
Issuance of common shares pursuant to exercise of options	1,172,000	-552,000			620,000
Issuance of common shares pursuant to exercise of options (in Shares)	172,937
Issuance of common shares pursuant to exercise of warrants	275,000				275,000
Issuance of common shares pursuant to exercise of warrants (in Shares)	11,500
Issuance of common shares in conjunction with the private offering, net of issuance costs of $9,700,000	142,175,000				142,175,000
Issuance of common shares in conjunction with the private offering, net of issuance costs of $9,700,000 (in Shares)	7,500,000
Issuance of common shares in conjunction with the acquisition of OnCore (note 3)	380,815,000				380,815,000
Issuance of common shares in conjunction with the acquisition of OnCore (note 3) (in Shares)	23,973,315
Currency translation adjustment				-9,174,000	-9,174,000
Net loss			-11,989,000		-11,989,000
Balance, at Mar. 31, 2015	$814,441,000	$28,590,000	($217,853,000)	($31,487,000)	$593,691,000
Balance, shares (in Shares) at Mar. 31, 2015	54,095,921

Condensed_Consolidated_Stateme2

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parentheticals) (Additional Paid-in Capital [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Additional Paid-in Capital [Member]
Issuance of common shares in conjunction with the private offering, net of issuance costs	$9,700,000

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flow (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
OPERATING ACTIVITIES
Net income (loss) for the period	($11,989,000)	($17,984,000)
Items not involving cash:
Depreciation of property and equipment	120,000	134,000
Change in fair value of warrant liability	1,223,000	13,616,000
Net change in non-cash operating items:
Accounts receivable	-2,886,000	-1,409,000
Accrued revenue	-1,126,000	-208,000
Deferred expenses		55,000
Prepaid expenses and other assets	221,000	482,000
Accounts payable and accrued liabilities	2,008,000	1,051,000
Deferred revenue	-1,291,000	12,289,000
Net cash provided by (used in) operating activities	-17,843,000	9,155,000
INVESTING ACTIVITIES
Disposition of short-term investments	37,363,000
Cash acquired through acquisition of OnCore (note 3)	324,000
Acquisition of property and equipment	-141,000	-335,000
Net cash provided by (used) in investing activities	37,546,000	-335,000
FINANCING ACTIVITIES
Proceeds from issuance of common shares, net of issuance costs	142,175,000	56,477,000
Issuance of common shares pursuant to exercise of options	620,000	1,924,000
Issuance of common shares pursuant to exercise of warrants	25,000	888,000
Net cash provided by financing activities	142,820,000	59,289,000
Effect of foreign exchange rate changes on cash and cash equivalents	-2,434,000	-2,469,000
Increase in cash and cash equivalents	160,089,000	65,640,000
Cash and cash equivalents, beginning of period	72,187,000	68,717,000
Cash and cash equivalents, end of period	232,276,000	134,357,000
Supplemental cash flow information
Acquisition of OnCore exclusing cash acquired	381,618,000
Research and Development Expense [Member]
Items not involving cash:
Stock Based Compensation	2,157,000	848,000
Unrealized foreign exchange (gains) losses	-7,057,000	-59,000
Change in fair value of warrant liability	1,223,000	13,616,000
General and Administrative Expense [Member]
Items not involving cash:
Stock Based Compensation	$777,000	$340,000

Note_1_Nature_of_Business_and_

Note 1 - Nature of Business and Future Operations	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Nature of Operations [Text Block]	1. Nature of business and future operations
	Tekmira Pharmaceuticals Corporation (the “Company”) is a Canadian biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection (“HBV”), a disease of the liver caused by hepatitis B virus (“HBV”). The Company is also developing a pipeline focused on advancing novel RNA interference therapeutics (RNAi) leveraging the Company’s expertise in Lipid Nanoparticle (“LNP”) technology.
	The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The continuation of the research and development activities and the commercialization of its products are dependent on the Company’s ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of future research and development programs or the Company’s ability to fund these programs in the future.

Note_2_Significant_Accounting_

Note 2 - Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Significant accounting policies
	Basis of presentation
	Tekmira Pharmaceuticals Corporation was incorporated on October 6, 2005 as an inactive wholly owned subsidiary of Inex Pharmaceuticals Corporation (“Inex”). Pursuant to a “Plan of Arrangement” effective April 30, 2007, the business, and substantially all of the assets and liabilities of Inex were transferred to the Company. The consolidated financial statements for all periods presented herein include the consolidated operations of Inex until April 30, 2007 and the operations of the Company thereafter.
	These unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles of the United States of America (“U.S. GAAP”) for interim financial statements and accordingly, do not include all disclosures required for annual financial statements.  These statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2014 and included in the Company’s 2014 annual report on Form 10-K. The unaudited condensed consolidated financial statements reflect, in the opinion of management, all adjustments and reclassifications necessary to present fairly the financial position, results of operations and cash flows at March 31, 2015 and for all periods presented. The results of operations for the three months ended March 31, 2015 and March 31, 2014 are not necessarily indicative of the results for the full year. These condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2014, except as described below.
	Principles of consolidation
	The Company has five wholly-owned subsidiaries: Protiva Biotherapeutics Inc. (“Protiva”), Protiva Biotherapeutics (USA) Inc. (“Protiva USA”), Protiva Agricultural Development Company Inc. (“PADCo”), OnCore Biopharma, Inc. (“OnCore”) and Enantigen Therapeutics, Inc. (“Enantigen”) – see note 3.
	These condensed consolidated financial statements include the accounts of the Company and four of its wholly-owned subsidiaries, Protiva, Protiva USA, OnCore and Enantigen. All intercompany transactions and balances have been eliminated on consolidation.
	The Company records its investment in PADCo using the equity method. The Company has determined that PADCo is a variable interest entity (“VIE”) of which it is not the primary beneficiary. The Company is not the primary beneficiary as it does not have  the power to make decisions that most significantly affect the economic performance of the VIE nor does not have the right to receive benefits or the obligation to absorb losses that in either case could potentially be significant to the VIE. PADCo is described further in note 4(b).
	Replacement awards
	Replacement awards are share-based payment awards exchanged for awards held by employees of the acquiree. As part of the Company’s acquisition of OnCore, Tekmira shares were exchanged for OnCore shares subject to repurchase held by OnCore employees – see note 3.
	As at the date of acquisition, the Company determined the total fair value of replacement awards and attributed a portion of the replacement awards to precombination service as part of the total acquisition consideration, and a portion to postcombination service, which is recognized as compensation expense over the expiry period of repurchase provision rights subsequent to the acquisition date.
	Goodwill and intangible assets
	The costs incurred in establishing and maintaining patents for intellectual property developed internally are expensed in the period incurred.
	Intangible assets consist of in-process research and development arising from the Company’s acquisition of OnCore – see note 3. Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives, which are the respective patent terms. Amortization begins when intangible assets with finite lives are put into use. If there is a major event indicating that the carrying value of intangible assets may be impaired, then management will perform an impairment test and if the recoverable value, based on undiscounted future cash flows, exceeds the carrying value, then such assets are written down to their fair values.
	Goodwill represents the excess of purchase price over the value assigned to the net tangible and identifiable intangible assets of OnCore – see note 3. Goodwill has an indefinite accounting life and is therefore not amortized. Instead, goodwill is subject to a two-step impairment test on an annual basis, unless the Company identifies impairment indicators that would require earlier testing. The first step compares the fair value of the reporting unit to its carrying amount, which includes the goodwill. When the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not to be impaired, and the second step of the impairment test is unnecessary. If the carrying amount exceeds the implied fair value of the goodwill, the second step measures the amount of the impairment loss. If the carrying amount exceeds the fair value of the goodwill, an impairment loss is recognized equal to that excess.
	Income or loss per share
	Income or loss per share is calculated based on the weighted average number of common shares outstanding. Diluted loss per share does not differ from basic loss per share since the effect of the Company’s stock options and warrants is anti-dilutive. Diluted income per share is calculated using the treasury stock method which uses the weighted average number of common shares outstanding during the period and also includes the dilutive effect of potentially issuable common shares from outstanding, in-the-money stock options and warrants. At March 31, 2015, potential common shares of 2,917,441 (March 31, 2014 – 2,565,029) were excluded from the calculation of income per common share because their inclusion would be anti-dilutive.
	Fair value of financial instruments
	The Company measures certain financial instruments and other items at fair value.
	To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:
		•	Level 1 inputs are quoted market prices for identical instruments available in active markets.
		•	Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.
		•	Level 3 inputs are unobservable inputs for the asset or liability and will reflect management’s assumptions about market assumptions that would be used to price the asset or liability.
	The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis, in thousands, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:
	The Company used a discounted cash flow model to determine the fair value of the financial instrument, related to Monsanto’s call option to acquire the equity or all of the assets of PADCo, as described in note 4(b). The fair value was determined at the date of recognition, and at each reporting date. The initial fair value of the financial liability was nil, and there has been no change to its fair value as at March 31, 2015.
	Contingent consideration is a liability assumed by the Company from its acquisition of OnCore – see note 3 and 8. The fair value as at March 31, 2015 is preliminary and the Company is currently undertaking a valuation assessment of the contingent consideration.
			Level 1			Level 2			Level 3			31-Mar-15
	Assets
	Cash and cash equivalents		$	232,276			-			-		$	232,276
	Liabilities
	Warrants			-			-		$	5,623		$	5,623
	Contingent consideration			-			-			4,736			4,736
	Financial instrument			-			-			-			-
	Total			-			-		$	10,359		$	10,359
			Level 1			Level 2			Level 3			31-Dec-14
	Assets
	Cash and cash equivalents		$	72,187			-			-		$	72,187
	Guaranteed investment certificates			39,974			-			-			39,974
	Total		$	112,161			-			-		$	112,161
	Liabilities
	Warrants			-			-		$	5,099		$	5,099
	Financial instrument			-			-			-			-
	Total			-			-		$	5,099		$	5,099
	The following table presents the changes in fair value of the Company’s warrants, in thousands:
			Liability at beginning			Opening liability of			Fair value of			Increase in fair		Foreign exchange			Liability at end
			of the period			warrants issued in			warrants exercised			value of warrants		(gain) loss			of the period
						the period			in the period
	Three months ended March 31, 2014		$	5,379			-		$	(5,955	)	$	13,616	$	216		$	12,824
	Three months ended March 31, 2015		$	5,099			-		$	(250	)	$	1,223	$	(449	)	$	5,623
	The change in fair value of warrant liability for the three months ended March 31, 2015 is recorded in the statement of operations and comprehensive loss.
	The weighted average Black-Scholes option-pricing assumptions and the resultant fair values, in thousands, for warrants outstanding at March 31, 2015 and at December 31, 2014 are as follows:
	Warrant Pricing assumptions
			31-Mar-15			31-Dec-14
	Dividend yield			0	%		0	%
	Expected volatility			98.68	%		85.22	%
	Risk-free interest rate			0.49	%		1	%
	Expected average term (years)		0.6			0.5
	Fair value of warrants outstanding (per warrant)		$	14.54		$	12.8
	Aggregate fair value of warrants outstanding		$	5,623		$	5,099
	Number of warrants outstanding			386,750			398,250
	Foreign currency translation and reporting currency
	Functional currency
	The functional currency of the Company and its integrated subsidiaries (Protiva and Protiva USA) is the Canadian dollar. Foreign currency monetary assets and liabilities are translated into Canadian dollars at the rate of exchange prevailing at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. The previous month’s average rate of exchange is used to translate revenue and expense transactions. Exchange gains and losses are included in income or loss for the period.
	The local currency of OnCore (including its subsidiary, Enantigen) is the United States dollars which has been determined to be its functional currency, as it is the currency of the primary economic environment in which OnCore operates and expends cash. Foreign currency monetary assets and liabilities are translated into United States dollars at the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. The previous month’s average rate of exchange is used to translate revenue and expense transactions. Exchange gains and losses are included in income or loss for the period.
Reporting currency
The Company is using United States dollars as its reporting currency. All assets and liabilities are translated using the exchange rate at the balance sheet date. Revenues, expenses and other income (losses) are translated using the average rate for the period, except for large transactions, for which the exchange rate on the date of the transaction is used. Equity accounts are translated using the historical rate. The translation differences from the Company’s functional currency to the Company’s reporting currency of U.S. dollars are unrealized gains and losses; therefore, the differences are recorded in other comprehensive income (loss), and do not impact the calculation of Income or Loss per Share.
Recent accounting pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (ASC 606). The standard is intended to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP and IFRS by creating a new Topic 606, Revenue from Contracts with Customers. This guidance supersedes the revenue recognition requirements in ASC 605, Revenue Recognition, and supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition – Construction-Type and Production-Type Contracts. The core principle of the accounting standard is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those good or services. The amendments should be applied by either (1) retrospectively to each prior reporting period presented; or (2) retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. In April 2015, the FASB voted to propose a deferral of the effective date of the ASU by one year. The new guidance would be effective for fiscal years beginning after December 15, 2017 instead of December 15, 2016, which for the Company means January 1, 2018. Entities are permitted to adopt in accordance with the original effective date if they choose. The Company has not yet determined the extent of the impact of adoption.
In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The update is intended to provide guidance in GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Under amendments to GAAP, the assessment period is within one year after the date that the financial statements are issued (or available to be issued). The amendments are effective for the annual period ending after December 15, 2016, which for the Company means January 1, 2017, and for annual periods and interim periods thereafter. Early application is permitted.  The Company does not plan to early adopt this update. The extent on the impact of this adoption has not yet been determined.

Note_3_Merger_with_OnCore_Biop

Note 3 - Merger with OnCore Biopharma, Inc. (“OnCore”)	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	3. Merger with OnCore Biopharma, Inc. (“OnCore”)
	On January 11, 2015, the Company entered into a Merger Agreement to acquire 100% of the outstanding shares of OnCore and its wholly-owned subsidiary, Enantigen (see note 8). OnCore was a privately owned U.S. company focused on discovery, development and commercialization of an all-oral cure regimen for patients with HBV. The merger was approved by the Company’s shareholders on March 3, 2015 and consummated on March 4, 2015. OnCore’s results of operations and fair value of assets acquired and liabilities assumed are included in the Company’s consolidated financial statements from the date of acquisition.
	The transaction has been accounted for using the acquisition method based on ASC 805, Business Combinations, on the basis that Tekmira is the acquirer, based on managements’ analysis and evaluation of the form of the acquisition, the relative contribution and rights of the predecessor groups post-closing, and the relative number of shares issued by the Company on acquisition of OnCore. Under the acquisition method, the consideration transferred is measured at the market price as at the acquisition date. The excess of the purchase price over the preliminary value assigned to the net assets acquired has been recorded as goodwill. Acquisition costs are expensed as incurred. The company recorded $9,295,000 of acquisition costs for the three-months ended March 31, 2015.
	The Company issued a total of 23,973,315 common shares with a total value of $381,942,000 as consideration, which is comprised of 20,347,906 common shares issued without subjects and 3,625,412 common shares issued subject to repurchase provision. The fair value of the common shares issued without subjects has been determined to be the Company’s NASDAQ closing price of $18.26 on the date prior to the acquisition’s consummation, March 4, 2015. The total fair value of the common shares issued subject to repurchase provision has been determined to be $66,196,000, using the Black-Scholes pricing model with assumed risk-free interest rate of 0.74%, volatility of 81%, a zero dividend yield and an expected life of 4 years. Of the total fair value, $9,262,000 has been attributed as pre-combination service and included as part of the total acquisition consideration. The post-combination attribution of $56,934,000 will be recognized as compensation expense over the period of expiry of repurchase provision rights through to August 2018. The Company has included $1,205,000 compensation expense related to the expiration of repurchase provision rights from the acquisition date through to March 31, 2015.
	The Company has further reserved 184,332 shares for the future exercise of OnCore stock options. The total fair value of OnCore stock options has been determined to be $3,287,000, using the Black-Scholes pricing model with the same assumption inputs used by the Company to determine the fair value of Tekmira options. Of the total fair value, $1,127,000 has been attributed as pre-combination service and included as part of the total acquisition consideration. The post-combination attribution of $2,160,000 will be recognized as compensation expense over the vesting period of the stock options through to December 2018. The Company has included $44,000 compensation expense related to the vesting of OnCore stock options from the acquisition date through to March 31, 2015.
	The aggregate fair value of consideration transferred to acquire OnCore’s outstanding shares has been determined to be $381,942,000, and has been attributed to preliminary fair values of the assets acquired and liabilities assumed as summarized in the following table.
	Consideration paid:
	Common shares issued without subjects	$	371,553
	Common shares issued subject to repurchase provision		9,262
	Common shares issuable for OnCore stock options		1,127
		$	381,942
	Identifiable assets acquired and liabilities assumed:
	Cash	$	324
	Prepaid expenses and other assets		127
	Accounts receivable		8
	Property and equipment		147
	Acquired intangible assets		389,652
	Goodwill		155,865
	Accounts payable and accrued liabilities		(3,580	)
	Other noncurrent liabilities (note 8)		(4,736	)
	Deferred income tax liability		(155,865	)
	Total purchase price allocation	$	381,942
	A preliminary fair value of $389,652,000 has been allocated to intangible assets.
	Based on the preliminary fair values above, an amount of $155,865,000 has been allocated to goodwill attributable to synergies expected to arise after the Company’s acquisition of OnCore. Goodwill increased from the preliminary estimate of nil to $155,865,000 due to revision in the estimate of deferred tax liability. The full amount of the goodwill has been assigned to Tekmira, which is the reporting unit management has determined the goodwill to be associated with. The goodwill is not expected to be deductible for tax purposes.
	The above allocation to assets acquired and liabilities assumed are preliminary, as the Company is currently in the process of completing valuation assessments, including the calculation of fair values of separately identifiable intangible assets acquired. As the allocation is preliminary, it is subject to change and such changes could be material.
	The amount of net loss of OnCore included in our consolidated statements of operations from the acquisition date, through the period ended March 31, 2015 was $1,027,000. OnCore did not earn any revenues from the acquisition date through the period ended March 31, 2015.
	The following table presents the unaudited pro forma results for the three months ended March 31, 2015 and 2014. The pro forma financial information combines the results of operations of Tekmira, Protiva, Protiva USA, OnCore and Enantigen as though the businesses had been combined as of the beginning of fiscal 2014 and 2015. The pro forma financial information is presented for informational purposes only, and is not indicative of the results of operations that would have been achieved if the merger had taken place at the beginning of fiscal 2014 and 2015. The pro forma financial information presented includes acquisition costs, amortization charges for acquired tangible assets, but does not include amortization charges for acquired intangible assets as these assets have not yet been put in use.
		Three months ended March 31,
		2015			2014
	Pro forma information
	Gross Revenue	$	4,682		$	4,430
	Loss from operations		(25,071	)		(10,434	)
	Net loss		(19,054	)		(22,483	)
	Basic and diluted loss per share	$	(0.41	)	$	(0.51	)

Note_4_Collaborations_Contract

Note 4 - Collaborations, Contracts and Licensing Agreements	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative Arrangement Disclosure [Text Block]	4. Collaborations, contracts and licensing agreements
	The following tables set forth revenue recognized under collaborations, contracts and licensing agreements, in thousands:
		Three months ended March 31
		2015		2014
	Collaborations and contracts
	DoD (a)	$	3,045	$	3,240
	Monsanto (b)		248		243
	BMS (d)		-		206
	Dicerna (e)		227		-
	Total research and development collaborations and contracts		3,520		3,689
	Licensing fees, milestone and royalty payments
	Monsanto licensing fees and milestone payments (b)		842		545
	Acuitas milestone payments (c)		-		150
	Dicerna licensing fee (e)		263		-
	Spectrum royalty payments (f)		57		46
	Total licensing fees, milestone and royalty payments		1,162		741
	Total revenue	$	4,682	$	4,430
	The following table sets forth deferred collaborations and contracts revenue:
		31-Mar-15		31-Dec-14
	DoD (a)	$	222	$	313
	Monsanto current portion (b)		3,888		4,245
	Dicerna current portion (e)		1,123		1,221
	Deferred revenue, current portion		5,233		5,779
	Monsanto long-term portion (b)		6,965		8,666
	Dicerna long-term portion (e)		932		1,271
	Total deferred revenue	$	13,130	$	15,716
	(a)  Contract with United States Government’s Department of Defense (“DoD”) to develop TKM-Ebola
	On July 14, 2010, the Company signed a contract with the DoD to advance TKM-Ebola, an RNAi therapeutic utilizing the Company’s lipid nanoparticle technology to treat Ebola virus infection.
	In the initial phase of the contract, funded as part of the Transformational Medical Technologies program, the Company was eligible to receive up to $34,700,000. This initial funding is for the development of TKM-Ebola including completion of preclinical development, filing an Investigational New Drug application with the United States Food and Drug Administration (“FDA”) and completing a Phase 1 human safety clinical trial. On May 8, 2013, the Company announced that the contract had been modified to support development plans that integrate recent advancements in lipid nanoparticle (“LNP”) formulation and manufacturing technologies. The contract modification increased the stage one targeted funding by an additional $6,970,000. On April 22, 2014, the Company and the DoD signed a contract modification to further increase the stage one targeted funding by $2,100,000 to $43,819,000. The additional funding is to compensate the Company for unrecovered overheads related to the temporary stop-work period that occurred in 2012 and to provide additional overhead funding should it be required.
	The DoD has the option of extending the contract beyond the initial funding period to support the advancement of TKM-Ebola through to the completion of clinical development and FDA approval. Based on the contract’s budget this would provide the Company with up to $140,000,000 in funding for the entire program. In October 2014, the Company and the DoD exercised an option to add $7,000,000 for the manufacture of TKM-Ebola-Guinea (the “Ebola-Guinea Amendment”), developed by the Company, targeting the Ebola-Guinea strain responsible for the current outbreak in West Africa.
	Under the contract, the Company is reimbursed for costs incurred, including an allocation of overhead costs, and is paid an incentive fee. At the beginning of the fiscal year the Company estimates its labour and overhead rates for the year ahead. At the end of the year the actual labour and overhead rates are calculated and revenue is adjusted accordingly. The Company’s actual labour and overhead rates will differ from its estimated rates based on actual costs incurred and the proportion of the Company’s efforts on contracts and internal products versus indirect activities. Within minimum and maximum collars, the amount of incentive fee the Company can earn under the contract varies based on costs incurred versus budgeted costs.  During the contractual period, incentive fee revenue and total costs are impacted by management’s estimate and judgments which are continuously reviewed and adjusted as necessary using the cumulative catch-up method.  At March 31, 2015, the Company believes it can reliably estimate the final contract costs so has recognized the portion of expected incentive fee which has been earned to date.
	(b) Option and Services Agreements with Monsanto Company (“Monsanto”)
	On January 13, 2014, the Company and Monsanto signed an Option Agreement and a Services Agreement (together, the “Agreements”). Under the Agreements, Monsanto has an option to obtain a license to use the Company’s proprietary delivery technology and related intellectual property for use in agriculture. Over the option period, which is expected to be approximately four years, the Company will provide lipid formulations for Monsanto’s research and development activities, and Monsanto will make certain payments to the Company to maintain its option rights. The maximum potential value of the transaction, following the successful completion of milestones, is $86,200,000. From inception of the contract to March 31, 2015, the Company had received $17,500,000 in near term payments as outlined in the terms of the Agreements. The amounts received relate to research services and use of the Company’s technology over the option period, and are recognized as revenue on a straight-line basis over the option period.
	Under the Agreements, the Company has established a wholly-owned subsidiary, PADCo. The Company has determined that PADCo is a variable interest entity (“VIE”); however, Monsanto is the primary beneficiary of the arrangement. PADCo was established to perform research and development activities, which have been funded by Monsanto in return for a call option to acquire the equity or all of the assets of PADCo. At any time during the option period, Monsanto may choose to exercise its option, in which case Monsanto would pay the Company an option exercise fee and would receive a worldwide, exclusive right to use the Company’s proprietary delivery technology in the field of agriculture. Monsanto may elect to terminate this option at their discretion. The Company retains all rights to therapeutics uses of all current intellectual property and intellectual property developed under the Agreements. The Company’s initial investment is not significant, and has no implied or unfunded commitments and the maximum exposure to loss is limited to the amount of investment in the entity. The Company has included its investment in PADco in Other Assets. There were no significant assets or liabilities for PADCo as at March 31, 2015. There was no equity income or loss with respect to PADCo recorded for the quarter ended March 31, 2015.
	(c) License and collaboration with Alnylam Pharmaceuticals, Inc. (“Alnylam”) and Acuitas Therapeutics Inc. (“Acuitas”, formerly AlCana Technologies Inc.)
	Milestone receipts and payments
	In the three months ended March 31, 2014, the Company earned a $150,000 milestone from Acuitas, subsequent to Acuitas receiving a milestone payment from Alnylam with respect to Alnylam initiating a Phase III trial for ALN-TTR02.
	Arbitration with Alnylam and Ascletis Pharmaceuticals (Hangzhou) Co. Ltd. (“Ascletis”)
	On June 21, 2013, the Company transferred manufacturing process technology to Ascletis to enable them to produce ALN-VSP, a product candidate licensed to them by Alnylam. The Company believes that under the new licensing agreement with Alnylam, the technology transfer to Ascletis triggers a $5,000,000 milestone obligation from Alnylam to the Company. However, Alnylam has demanded a declaration that the Company has not yet met its milestone obligations. The Company disputes Alnylam’s position. To remedy this dispute, the Company and Alnylam have commenced arbitration proceedings as provided for under the agreement. The hearing date for this arbitration is currently set for the second week in May 2015. The Company has not recorded any revenue in respect of this milestone.
	(d) Bristol-Myers Squibb (“BMS”) collaboration
	On May 10, 2010 the Company announced the expansion of its research collaboration with BMS. Under the new agreement, BMS uses small interfering RNA (“siRNA”) molecules formulated by the Company in LNP technology to silence target genes of interest.  BMS is conducting the preclinical work to validate the function of certain genes and share the data with the Company.  The Company could use the preclinical data to develop RNAi therapeutic drugs against the therapeutic targets of interest.  The Company received $3,000,000 from BMS concurrent with the signing of the agreement and recorded the amount as deferred revenue. The Company was required to provide a pre-determined number of LNP batches over the four-year agreement.  BMS had a first right to negotiate a licensing agreement on certain RNAi products developed by the Company that evolve from BMS validated gene targets.
	Revenue from the May 10, 2010 agreement with BMS was being recognized as the Company produces the related LNP batches.
	The revenue earned for the three months ended March 31, 2014 was related to BMS batches shipped during the period. In August 2014, the agreement expired and both companies’ obligations under the agreement ended.
	(e) License and Development and Supply Agreement with Dicerna Pharmaceuticals, Inc. (“Dicerna”)
	On November 16, 2014, the Company signed a License Agreement and a Development and Supply Agreement (together, the “Agreements”) with Dicerna to develop, manufacture, and commercialize products directed to the treatment of Primary Hyperoxaluria 1 (“PH1”). In consideration for the rights granted under the Agreements, Dicerna paid the Company an upfront cash payment of $2,500,000. The Company is also entitled to receive payments from Dicerna on manufacturing and services provided, as well as further payments with the achievement of development and regulatory milestones of up to $22,000,000, in aggregate, and potential commercial royalties. Further, under the Agreements, a joint development committee has been established to provide guidance and direction on the progression of the collaboration.
	The Company determined the deliverables under the Agreements included the rights granted, participation in the joint development committee, materials manufactured and other services provided, as directed under the joint development committee. The Company has determined that manufacturing services and other services provided have standalone value, as a separate statement of work is executed and invoiced for each manufacturing or service work order. The relative fair values are determined as a batch price or fee is estimated upon the execution of each work order, with actual expenditures charged at comparable market rates with embedded margins on each work order. Manufacturing work orders are invoiced at the time of execution of the work order, at the initiation of manufacture, and at the release of materials. Revenue from service work orders is recognized as the services are performed. The license and participation in the joint development committee have been determined by the Company to not have standalone value due to the uniqueness of the subject matter under the Agreements. Therefore, these deliverables are treated as one unit of accounting and recognized as revenue over the performance period, which the Company has estimated to be approximately 28 months as at March 31, 2015 (December 31, 2014 – 28 months).
	The Company believes the development and regulatory milestones are substantive, due to the existence of substantive uncertainty upon the execution of the arrangement, and that the achievement of the development and regulatory events are based, in part, on the Company’s performance and the occurrence of a specific outcome resulting from performance. The Company has not received any milestone payments to date.
	(f) Agreements with Spectrum Pharmaceuticals, Inc. (“Spectrum”)
	On May 6, 2006, the Company signed a number of agreements with Talon Therapeutics, Inc. (“Talon”, formerly Hana Biosciences, Inc.) including the grant of worldwide licenses (the “Talon License Agreement”) for three of the Company’s chemotherapy products, Marqibo®, AlocrestTM (Optisomal Vinorelbine) and BrakivaTM (Optisomal Topotecan).
	On August 9, 2012, the Company announced that Talon had received accelerated approval for Marqibo from the FDA for the treatment of adult patients with Philadelphia chromosome negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Marqibo is a liposomal formulation of the chemotherapy drug vincristine. There are no further milestones related to Marqibo but the Company is eligible to receive total milestone payments of up to $18,000,000 on Alocrest and Brakiva.
	Talon was acquired by Spectrum in July 2013. The acquisition does not affect the terms of the license between Talon and the Company. On September 3, 2013, Spectrum announced that they had shipped the first commercial orders of Marqibo. For the three months ended March 31, 2015, the Company recorded $57,000 in Marqibo royalty revenue (three months ended March 31, 2014 - $46,000). For the three months ended March 31, 2015, the Company accrued 2.5% in royalties due to TPC in respect of the Marqibo royalty earned by the Company – see note 8, contingencies and commitments.

Note_5_Accounts_Payable_and_Ac

Note 5 - Accounts Payable and Accrued Liabilities	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	5. Accounts payable and accrued liabilities
	Accounts payable and accrued liabilities is comprised of the following, in thousands:
		31-Mar-15		31-Dec-14
	Trade accounts payable	$	7,242	$	2,044
	Research and development accruals		3,417		2,391
	License fee accruals		-		250
	Professional fee accruals		1,746		1,294
	Deferred lease inducements		335		250
	Payroll accruals		28		2,873
	Other accrued liabilities		1,251		226
		$	14,019	$	9,328

Note_6_Financing

Note 6 - Financing	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	6. Financing
	On March 25, 2015, the Company announced that it had completed an underwritten public offering of 7,500,000 common shares, at a price of $20.25 per share, representing gross proceeds of $151,875,000. The Company also granted the underwriters a 30-day option to purchase an additional 1,125,000 shares for an additional $22,781,000 to cover any over-allotments. The underwriters did not exercise the option. The cost of financing, including commissions and professional fees, was $9,700,000, resulting in net proceeds of $142,175,000.

Note_7_Concentrations_of_Credi

Note 7 - Concentrations of Credit Risk	3 Months Ended
	Mar. 31, 2015
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	7. Concentrations of credit risk
	Credit risk is defined by the Company as an unexpected loss in cash and earnings if a collaborative partner is unable to pay its obligations in due time.  The Company’s main source of credit risk is related to its accounts receivable balance which principally represents temporary financing provided to collaborative partners in the normal course of operations.
	The Company does not currently maintain a provision for bad debts as the majority of accounts receivable are from collaborative partners or government agencies and are considered low risk.
	The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at March 31, 2015 was the accounts receivable balance of $4,564,000 (December 31, 2014 - $1,903,000).
	All accounts receivable balances were current as at March 31, 2015 and at December 31, 2014.

Note_8_Contingencies_and_Commi

Note 8 - Contingencies and Commitments	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	8. Contingencies and commitments
	Product development partnership with the Canadian Government
	The Company entered into a Technology Partnerships Canada ("TPC") agreement with the Canadian Federal Government on November 12, 1999.  Under this agreement, TPC agreed to fund 27% of the costs incurred by the Company, prior to March 31, 2004, in the development of certain oligonucleotide product candidates up to a maximum contribution from TPC of $7,179,000 (C$9,323,000).  As at March 31, 2015, a cumulative contribution of $2,923,000 (C$3,702,000) has been received and the Company does not expect any further funding under this agreement.  In return for the funding provided by TPC, the Company agreed to pay royalties on the share of future licensing and product revenue, if any, that is received by the Company on certain non-siRNA oligonucleotide product candidates covered by the funding under the agreement.  These royalties are payable until a certain cumulative payment amount is achieved or until a pre-specified date.  In addition, until a cumulative amount equal to the funding actually received under the agreement has been paid to TPC, the Company agreed to pay 2.5% royalties on any royalties the Company receives for Marqibo. For the three months ended March 31, 2015, the Company earned royalties on Marqibo sales in the amount of $57,000 (three months ended March 31, 2014 – $46,000) (see note 4(f)), resulting in $1,000 being recorded by the Company as royalty payable to TPC (March 31, 2014 - $1,000). The cumulative amount paid or accrued up to March 31, 2015 was $1,000, resulting in the contingent amount due to TPC being $2,916,000 (C$3,694,000).
	License agreement with Marina Biotech, Inc. (“Marina”)
	On November 29, 2012 the Company announced a worldwide, non-exclusive license to a novel RNAi payload technology called Unlocked Nucleobase Analog (“UNA”) from Marina for the development of RNAi therapeutics.
	UNA technology can be used in the development of RNAi therapeutics, which treat disease by silencing specific disease causing genes. UNAs can be incorporated into RNAi drugs and have the potential to improve them by increasing their stability and reducing off-target effects.
	Under the license agreement the Company paid Marina an upfront fee of $300,000 during the year ended December 31, 2012. A further license payment of $200,000 was paid in 2013 and the Company will make milestone payments of up to $3,250,000 and royalties on each product developed by the Company that uses Marina’s UNA technology. The payments to Marina are expensed to research, development, collaborations and contracts expense.
	Effective August 9, 2013, Marina’s UNA technology was acquired by Arcturus Therapeutics, Inc. (“Arcturus”) and the UNA license agreement between the Company and Marina was assigned to Arcturus. The terms of the license are otherwise unchanged. On December 22, 2014, the Company received clearance from Health Canada to conduct a Phase I Clinical Study with TKM-HBV, which utilizes Arcturus’ UNA technology. This triggered the accrual of $250,000 as at December 31, 2014 related to the milestone payable to Arcturus upon the dosing of first subject in a Phase I clinical trial of TKM-HBV, which occurred on January 21, 2015.
	Arbitration with the University of British Columbia (“UBC”)
	Certain early work on lipid nanoparticle delivery systems and related inventions was undertaken at UBC.  These inventions are licensed to the Company by UBC under a license agreement, initially entered in 1998 as amended in 2001, 2006 and 2007. The Company has granted sublicenses under the UBC license to Alnylam as well as to Spectrum.  Alnylam has in turn sublicensed back to the Company under the licensed UBC patents for discovery, development and commercialization of RNAi products. In 2009, the Company entered into a supplemental agreement with UBC, Alnylam and Acuitas, in relation to a separate research collaboration to be conducted among UBC, Alnylam and Acuitas to which the Company has license rights. The settlement agreement signed in late 2012 to resolve the litigation among the Company, Alnylam, and Acuitas, provided for the effective termination of all obligations under such supplemental agreement as between and among all litigants.
	On November 10, 2014, UBC filed a notice of arbitration against the Company and on January 16, 2015, filed a Statement of Claim, which alleges entitlement to $3,500,000 in allegedly unpaid royalties based on publicly available information, and an unspecified amount based on non-public information. UBC also seeks interest and costs, including legal fees. The Company is currently disputing UBC’s allegations, and no dates have been scheduled for this arbitration. The Company has not recorded an estimate of the possible loss associated with this arbitration, due to the uncertainties related to both the likelihood and amount of any possible loss or range of loss. Costs related to the arbitration have been recorded by the Company as incurred.
	Contingent consideration from OnCore acquisition of Enantigen and License Agreements between Enantigen and Blumberg and Drexel
	In October 2014, OnCore acquired all of the outstanding shares of Enantigen pursuant to a stock purchase agreement. Through this transaction, OnCore acquired a HBV surface antigen secretion inhibitor program and a capsid assembly inhibitor program, each of which are now assets of Tekmira, following the Company’s merger with OnCore – see note 3.
	Under the stock purchase agreement, OnCore agreed to pay up to a total of $21,000,000 to Enantigen’s selling stockholders upon the achievement of certain triggering events related to Enantigen’s two programs in pre-clinical development related to HBV therapies. The first triggering event is the enrollment of first patient in Phase 1b clinical trial in HBV patients, which the Company does not expect to occur in the next twelve-month period.
	The regulatory milestone payments have an estimated fair value of approximately $4,736,000 and have been treated as contingent consideration payable in the preliminary purchase price allocation (note 3), based on information available including OnCore’s valuation at the date of its acquisition of Enantigen, using a probability weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments, and then the potential contingent payments were discounted to their present value using a probability adjusted discount rate of 17.7% (reflecting the early stage nature of the development program, time to complete the program development, and overall biotech indices).
	As part of its acquisition of OnCore on March 4, 2015 as described in note 3, the other non-current liabilities assumed by the Company included the contingent consideration of $4,736,000 related to OnCore’s acquisition of Enantigen. The Company is currently undertaking valuation assessments of assets acquired and liabilities assumed from OnCore, which includes a valuation assessment of the contingent consideration.
	Drexel and Blumberg
	In February 2014, OnCore entered into a license agreement with Blumberg and Drexel that granted an exclusive, worldwide, sub-licensable license to three different compound series: cccDNA inhibitors, capsid assembly inhibitors and HCC inhibitors.
	In partial consideration for this license, OnCore paid a license initiation fee of $150,000 and issued warrants to Blumberg and Drexel. Under this license agreement, OnCore also agreed to pay up to $3,500,000 in development and regulatory milestones per licensed compound series, up to $92,500,000 in sales performance milestones per licensed product, and royalties in the mid-single digits based upon the proportionate net sales of licensed products in any commercialized combination. The Company is obligated to pay Blumberg and Drexel a double digit percentage of all amounts received from the sub-licensees, subject to customary exclusions.
	In November 2014, OnCore entered into an additional license agreement with Blumberg and Drexel pursuant to which it received an exclusive, worldwide, sub-licensable license under specified patents and know-how controlled by Blumberg and Drexel covering epigenetic modifiers of cccDNA and STING agonists. In consideration for these exclusive licenses, OnCore made an upfront payment of $50,000. Under this agreement, the Company will be required to pay up to $1,000,000 for each licensed product upon the achievement of a specified regulatory milestone and a low single digit royalty, based upon the proportionate net sales of compounds covered by this intellectual property in any commercialized combination. The Company is also obligated to pay Blumberg and Drexel a double digit percentage of all amounts received from its sub-licensees, subject to exclusions.
	Research Collaboration and Funding Agreement with Blumberg
	In October 2014, OnCore entered into a research collaboration and funding agreement with Blumberg under which the Company will provide $1,000,000 per year of research funding for three years, renewable at our option for an additional three years, for Blumberg to conduct research projects in HBV and liver cancer pursuant to a research plan to be agreed upon by the parties. Blumberg has exclusivity obligations to Tekmira with respect to HBV research funded under the agreement. In addition, we have the right to match any third party offer to fund HBV research that falls outside the scope of the research being funded under the agreement. Blumberg has granted us the right to obtain an exclusive, royalty bearing, worldwide license to any intellectual property generated by any funded research project. If the Company elects to exercise our right to obtain such a license, the Company will have a specified period of time to negotiate and enter into a mutually agreeable license agreement with Blumberg. This license agreement will include the following pre negotiated upfront, milestone and royalty payments: an upfront payment in the amount of $100,000; up to $8,100,000 upon the achievement of specified development and regulatory milestones; up to $92,500,000 upon the achievement of specified commercialization milestones; and royalties at a low single to mid-single digit rates based upon the proportionate net sales of licensed products from any commercialized combination.
	NeuroVive Pharmaceutical AB (“NeuroVive”)
	In September 2014, OnCore entered into a license agreement with NeuroVive that granted us an exclusive, worldwide, sub-licensable license to develop, manufacture and commercialize, for the treatment of HBV, oral dosage form sanglifehrin based cyclophilin inhibitors (including OCB-030). Under this license agreement, the Company has been granted a non-exclusive, royalty free right and license and right of reference to NeuroVive’s relevant regulatory approvals and filings for the sole purpose of developing, manufacturing and commercializing licensed products for the treatment of HBV. Under this license agreement, we have (1) an option to expand our exclusive license to include treatment of viral diseases other than HBV and (2) an option, exercisable upon specified conditions, to expand our exclusive license to include development, manufacture and commercialization of non-oral variations of licensed products for treatment of viral diseases other than HBV. NeuroVive retains all rights with respect to development, manufacture and commercialization of licensed products and non-oral variations of licensed products for all indications (other than HBV) for which we have not exercised our option.
	In partial consideration for this license, OnCore paid NeuroVive a license fee of $1,000,000. The Company is also obligated to pay up to $47,000,000 in clinical development and regulatory milestones per indication and up to $102,500,000 in sales performance milestones per licensed product and indication. If we are acquired by a third party in a transaction that meets certain criteria, then we or our acquiror will be obligated to pay all remaining development, regulatory and sales milestone payments, regardless of whether the applicable milestone events have been achieved, for each licensed product that entered clinical development before such acquisition. We agreed to pay NeuroVive tiered royalties in the mid-single to low-double digit range based upon the proportionate gross sales of patented licensed products from any commercialized combination. If the Company terminates this license agreement in its entirety for convenience prior to the first commercial sale of any licensed product, we will be obligated to pay NeuroVive a termination fee of $2,000,000.
	Cytos Biotechnology Ltd (“Cytos”)
	On December 30, 2014, OnCore entered into an exclusive, worldwide, sub-licensable (subject to certain restrictions with respect to licensed viral infections other than hepatitis) license to six different series of compounds. The licensed compounds are Qbeta-derived virus-like particles that encapsulate TLR9, TLR7 or RIG-I agonists and may or may not be conjugated with antigens from the hepatitis virus or other licensed viruses.  The Company has an option to expand this license to include additional viral infections other than influenza and Cytos will retain all rights for influenza, all non-viral infections, and all viral infections (other than hepatitis) for which we have not exercised an option.
	In partial consideration for this license, upon closing of the Cytos Agreement, the Comapny will be obligated to pay Cytos up to a total of $67,000,000 for each of the six licensed compound series upon the achievement of specified development and regulatory milestones; for hepatitis and each additional licensed viral infection, up to a total of $110,000,000 upon the achievement of specified sales performance milestones; and tiered royalty payments in the high-single to low-double digits, based upon the proportionate net sales of licensed products in any commercialized combination.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of presentation
	Tekmira Pharmaceuticals Corporation was incorporated on October 6, 2005 as an inactive wholly owned subsidiary of Inex Pharmaceuticals Corporation (“Inex”). Pursuant to a “Plan of Arrangement” effective April 30, 2007, the business, and substantially all of the assets and liabilities of Inex were transferred to the Company. The consolidated financial statements for all periods presented herein include the consolidated operations of Inex until April 30, 2007 and the operations of the Company thereafter.
	These unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles of the United States of America (“U.S. GAAP”) for interim financial statements and accordingly, do not include all disclosures required for annual financial statements.  These statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2014 and included in the Company’s 2014 annual report on Form 10-K. The unaudited condensed consolidated financial statements reflect, in the opinion of management, all adjustments and reclassifications necessary to present fairly the financial position, results of operations and cash flows at March 31, 2015 and for all periods presented. The results of operations for the three months ended March 31, 2015 and March 31, 2014 are not necessarily indicative of the results for the full year. These condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2014, except as described below.
Consolidation, Policy [Policy Text Block]	Principles of consolidation
	The Company has five wholly-owned subsidiaries: Protiva Biotherapeutics Inc. (“Protiva”), Protiva Biotherapeutics (USA) Inc. (“Protiva USA”), Protiva Agricultural Development Company Inc. (“PADCo”), OnCore Biopharma, Inc. (“OnCore”) and Enantigen Therapeutics, Inc. (“Enantigen”) – see note 3.
	These condensed consolidated financial statements include the accounts of the Company and four of its wholly-owned subsidiaries, Protiva, Protiva USA, OnCore and Enantigen. All intercompany transactions and balances have been eliminated on consolidation.
	The Company records its investment in PADCo using the equity method. The Company has determined that PADCo is a variable interest entity (“VIE”) of which it is not the primary beneficiary. The Company is not the primary beneficiary as it does not have  the power to make decisions that most significantly affect the economic performance of the VIE nor does not have the right to receive benefits or the obligation to absorb losses that in either case could potentially be significant to the VIE. PADCo is described further in note 4(b).
Business Combinations Policy [Policy Text Block]	Replacement awards
	Replacement awards are share-based payment awards exchanged for awards held by employees of the acquiree. As part of the Company’s acquisition of OnCore, Tekmira shares were exchanged for OnCore shares subject to repurchase held by OnCore employees – see note 3.
	As at the date of acquisition, the Company determined the total fair value of replacement awards and attributed a portion of the replacement awards to precombination service as part of the total acquisition consideration, and a portion to postcombination service, which is recognized as compensation expense over the expiry period of repurchase provision rights subsequent to the acquisition date.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill and intangible assets
	The costs incurred in establishing and maintaining patents for intellectual property developed internally are expensed in the period incurred.
	Intangible assets consist of in-process research and development arising from the Company’s acquisition of OnCore – see note 3. Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives, which are the respective patent terms. Amortization begins when intangible assets with finite lives are put into use. If there is a major event indicating that the carrying value of intangible assets may be impaired, then management will perform an impairment test and if the recoverable value, based on undiscounted future cash flows, exceeds the carrying value, then such assets are written down to their fair values.
	Goodwill represents the excess of purchase price over the value assigned to the net tangible and identifiable intangible assets of OnCore – see note 3. Goodwill has an indefinite accounting life and is therefore not amortized. Instead, goodwill is subject to a two-step impairment test on an annual basis, unless the Company identifies impairment indicators that would require earlier testing. The first step compares the fair value of the reporting unit to its carrying amount, which includes the goodwill. When the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not to be impaired, and the second step of the impairment test is unnecessary. If the carrying amount exceeds the implied fair value of the goodwill, the second step measures the amount of the impairment loss. If the carrying amount exceeds the fair value of the goodwill, an impairment loss is recognized equal to that excess.
Earnings Per Share, Policy [Policy Text Block]	Income or loss per share
	Income or loss per share is calculated based on the weighted average number of common shares outstanding. Diluted loss per share does not differ from basic loss per share since the effect of the Company’s stock options and warrants is anti-dilutive. Diluted income per share is calculated using the treasury stock method which uses the weighted average number of common shares outstanding during the period and also includes the dilutive effect of potentially issuable common shares from outstanding, in-the-money stock options and warrants. At March 31, 2015, potential common shares of 2,917,441 (March 31, 2014 – 2,565,029) were excluded from the calculation of income per common share because their inclusion would be anti-dilutive.
Fair Value Measurement, Policy [Policy Text Block]	Fair value of financial instruments
	The Company measures certain financial instruments and other items at fair value.
	To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:
		•	Level 1 inputs are quoted market prices for identical instruments available in active markets.
		•	Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.
		•	Level 3 inputs are unobservable inputs for the asset or liability and will reflect management’s assumptions about market assumptions that would be used to price the asset or liability.
	The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis, in thousands, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:
	The Company used a discounted cash flow model to determine the fair value of the financial instrument, related to Monsanto’s call option to acquire the equity or all of the assets of PADCo, as described in note 4(b). The fair value was determined at the date of recognition, and at each reporting date. The initial fair value of the financial liability was nil, and there has been no change to its fair value as at March 31, 2015.
	Contingent consideration is a liability assumed by the Company from its acquisition of OnCore – see note 3 and 8. The fair value as at March 31, 2015 is preliminary and the Company is currently undertaking a valuation assessment of the contingent consideration.
			Level 1			Level 2			Level 3			31-Mar-15
	Assets
	Cash and cash equivalents		$	232,276			-			-		$	232,276
	Liabilities
	Warrants			-			-		$	5,623		$	5,623
	Contingent consideration			-			-			4,736			4,736
	Financial instrument			-			-			-			-
	Total			-			-		$	10,359		$	10,359
			Level 1			Level 2			Level 3			31-Dec-14
	Assets
	Cash and cash equivalents		$	72,187			-			-		$	72,187
	Guaranteed investment certificates			39,974			-			-			39,974
	Total		$	112,161			-			-		$	112,161
	Liabilities
	Warrants			-			-		$	5,099		$	5,099
	Financial instrument			-			-			-			-
	Total			-			-		$	5,099		$	5,099
	The following table presents the changes in fair value of the Company’s warrants, in thousands:
			Liability at beginning			Opening liability of			Fair value of			Increase in fair		Foreign exchange			Liability at end
			of the period			warrants issued in			warrants exercised			value of warrants		(gain) loss			of the period
						the period			in the period
	Three months ended March 31, 2014		$	5,379			-		$	(5,955	)	$	13,616	$	216		$	12,824
	Three months ended March 31, 2015		$	5,099			-		$	(250	)	$	1,223	$	(449	)	$	5,623
	The change in fair value of warrant liability for the three months ended March 31, 2015 is recorded in the statement of operations and comprehensive loss.
	The weighted average Black-Scholes option-pricing assumptions and the resultant fair values, in thousands, for warrants outstanding at March 31, 2015 and at December 31, 2014 are as follows:
	Warrant Pricing assumptions
			31-Mar-15			31-Dec-14
	Dividend yield			0	%		0	%
	Expected volatility			98.68	%		85.22	%
	Risk-free interest rate			0.49	%		1	%
	Expected average term (years)		0.6			0.5
	Fair value of warrants outstanding (per warrant)		$	14.54		$	12.8
	Aggregate fair value of warrants outstanding		$	5,623		$	5,099
	Number of warrants outstanding			386,750			398,250
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation and reporting currency
	Functional currency
	The functional currency of the Company and its integrated subsidiaries (Protiva and Protiva USA) is the Canadian dollar. Foreign currency monetary assets and liabilities are translated into Canadian dollars at the rate of exchange prevailing at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. The previous month’s average rate of exchange is used to translate revenue and expense transactions. Exchange gains and losses are included in income or loss for the period.
	The local currency of OnCore (including its subsidiary, Enantigen) is the United States dollars which has been determined to be its functional currency, as it is the currency of the primary economic environment in which OnCore operates and expends cash. Foreign currency monetary assets and liabilities are translated into United States dollars at the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. The previous month’s average rate of exchange is used to translate revenue and expense transactions. Exchange gains and losses are included in income or loss for the period.
	Reporting currency
	The Company is using United States dollars as its reporting currency. All assets and liabilities are translated using the exchange rate at the balance sheet date. Revenues, expenses and other income (losses) are translated using the average rate for the period, except for large transactions, for which the exchange rate on the date of the transaction is used. Equity accounts are translated using the historical rate. The translation differences from the Company’s functional currency to the Company’s reporting currency of U.S. dollars are unrealized gains and losses; therefore, the differences are recorded in other comprehensive income (loss), and do not impact the calculation of Income or Loss per Share.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent accounting pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (ASC 606). The standard is intended to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP and IFRS by creating a new Topic 606, Revenue from Contracts with Customers. This guidance supersedes the revenue recognition requirements in ASC 605, Revenue Recognition, and supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition – Construction-Type and Production-Type Contracts. The core principle of the accounting standard is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those good or services. The amendments should be applied by either (1) retrospectively to each prior reporting period presented; or (2) retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. In April 2015, the FASB voted to propose a deferral of the effective date of the ASU by one year. The new guidance would be effective for fiscal years beginning after December 15, 2017 instead of December 15, 2016, which for the Company means January 1, 2018. Entities are permitted to adopt in accordance with the original effective date if they choose. The Company has not yet determined the extent of the impact of adoption.
	In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The update is intended to provide guidance in GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Under amendments to GAAP, the assessment period is within one year after the date that the financial statements are issued (or available to be issued). The amendments are effective for the annual period ending after December 15, 2016, which for the Company means January 1, 2017, and for annual periods and interim periods thereafter. Early application is permitted.  The Company does not plan to early adopt this update. The extent on the impact of this adoption has not yet been determined.

Note_2_Significant_Accounting_1

Note 2 - Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Fair Value, Assets Measured on Recurring Basis [Table Text Block]		Level 1			Level 2			Level 3			31-Mar-15
	Assets
	Cash and cash equivalents	$	232,276			-			-		$	232,276
	Liabilities
	Warrants		-			-		$	5,623		$	5,623
	Contingent consideration		-			-			4,736			4,736
	Financial instrument		-			-			-			-
	Total		-			-		$	10,359		$	10,359
		Level 1			Level 2			Level 3			31-Dec-14
	Assets
	Cash and cash equivalents	$	72,187			-			-		$	72,187
	Guaranteed investment certificates		39,974			-			-			39,974
	Total	$	112,161			-			-		$	112,161
	Liabilities
	Warrants		-			-		$	5,099		$	5,099
	Financial instrument		-			-			-			-
	Total		-			-		$	5,099		$	5,099
Changes In Fair Value Of Warrants [Table Text Block]		Liability at beginning			Opening liability of			Fair value of			Increase in fair		Foreign exchange			Liability at end
		of the period			warrants issued in			warrants exercised			value of warrants		(gain) loss			of the period
					the period			in the period
	Three months ended March 31, 2014	$	5,379			-		$	(5,955	)	$	13,616	$	216		$	12,824
	Three months ended March 31, 2015	$	5,099			-		$	(250	)	$	1,223	$	(449	)	$	5,623
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
		31-Mar-15			31-Dec-14
	Dividend yield		0	%		0	%
	Expected volatility		98.68	%		85.22	%
	Risk-free interest rate		0.49	%		1	%
	Expected average term (years)	0.6			0.5
	Fair value of warrants outstanding (per warrant)	$	14.54		$	12.8
	Aggregate fair value of warrants outstanding	$	5,623		$	5,099
	Number of warrants outstanding		386,750			398,250

Note_3_Merger_with_OnCore_Biop1

Note 3 - Merger with OnCore Biopharma, Inc. (“OnCore”) (Tables)	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Consideration paid:
	Common shares issued without subjects	$	371,553
	Common shares issued subject to repurchase provision		9,262
	Common shares issuable for OnCore stock options		1,127
		$	381,942
	Identifiable assets acquired and liabilities assumed:
	Cash	$	324
	Prepaid expenses and other assets		127
	Accounts receivable		8
	Property and equipment		147
	Acquired intangible assets		389,652
	Goodwill		155,865
	Accounts payable and accrued liabilities		(3,580	)
	Other noncurrent liabilities (note 8)		(4,736	)
	Deferred income tax liability		(155,865	)
	Total purchase price allocation	$	381,942
Business Acquisition, Pro Forma Information [Table Text Block]		Three months ended March 31,
		2015			2014
	Pro forma information
	Gross Revenue	$	4,682		$	4,430
	Loss from operations		(25,071	)		(10,434	)
	Net loss		(19,054	)		(22,483	)
	Basic and diluted loss per share	$	(0.41	)	$	(0.51	)

Note_4_Collaborations_Contract1

Note 4 - Collaborations, Contracts and Licensing Agreements (Tables)	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]		Three months ended March 31
		2015		2014
	Collaborations and contracts
	DoD (a)	$	3,045	$	3,240
	Monsanto (b)		248		243
	BMS (d)		-		206
	Dicerna (e)		227		-
	Total research and development collaborations and contracts		3,520		3,689
	Licensing fees, milestone and royalty payments
	Monsanto licensing fees and milestone payments (b)		842		545
	Acuitas milestone payments (c)		-		150
	Dicerna licensing fee (e)		263		-
	Spectrum royalty payments (f)		57		46
	Total licensing fees, milestone and royalty payments		1,162		741
	Total revenue	$	4,682	$	4,430
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]		31-Mar-15		31-Dec-14
	DoD (a)	$	222	$	313
	Monsanto current portion (b)		3,888		4,245
	Dicerna current portion (e)		1,123		1,221
	Deferred revenue, current portion		5,233		5,779
	Monsanto long-term portion (b)		6,965		8,666
	Dicerna long-term portion (e)		932		1,271
	Total deferred revenue	$	13,130	$	15,716

Note_5_Accounts_Payable_and_Ac1

Note 5 - Accounts Payable and Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]		31-Mar-15		31-Dec-14
	Trade accounts payable	$	7,242	$	2,044
	Research and development accruals		3,417		2,391
	License fee accruals		-		250
	Professional fee accruals		1,746		1,294
	Deferred lease inducements		335		250
	Payroll accruals		28		2,873
	Other accrued liabilities		1,251		226
		$	14,019	$	9,328

Note_2_Significant_Accounting_2

Note 2 - Significant Accounting Policies (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Accounting Policies [Abstract]
Wholly Owned Subsidiaries	5
Wholly Owned Subsidiaries Included in Financial Statements	4
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,917,441	2,565,029

Note_2_Significant_Accounting_3

Note 2 - Significant Accounting Policies (Details) - Assets and Liabilities Measured at Fair Value (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
Assets
Cash and cash equivalents	$232,276,000	$72,187,000
Guaranteed investment certificates		39,974,000
Total		112,161,000
Liabilities
Warrants	5,623,000	5,099,000	12,824,000	5,379,000
Contingent consideration	4,736,000
Total	10,359,000	5,099,000
Fair Value, Inputs, Level 1 [Member]
Assets
Cash and cash equivalents	232,276,000	72,187,000
Guaranteed investment certificates		39,974,000
Total		112,161,000
Fair Value, Inputs, Level 3 [Member]
Liabilities
Warrants	5,623,000	5,099,000
Contingent consideration	4,736,000
Total	$10,359,000	$5,099,000

Note_2_Significant_Accounting_4

Note 2 - Significant Accounting Policies (Details) - Changes in Fair Value of the Company’s Warrants (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Changes in Fair Value of the Company’s Warrants [Abstract]
Liability at beginning of the period	$5,099	$5,379
Fair value of warrants exercised in the period	-250	-5,955
Increase in fir value of warrants	1,223	13,616
Foreign exchange (gain) loss	-449	216
Liability at end of the period	$5,623	$12,824

Note_2_Significant_Accounting_5

Note 2 - Significant Accounting Policies (Details) - Black-Scholes Option-pricing Assumptions (USD $)	3 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Black-Scholes Option-pricing Assumptions [Abstract]
Dividend yield	0.00%	0.00%
Expected volatility	98.68%	85.22%
Risk-free interest rate	0.49%	1.00%
Expected average term (years)	219 days	6 months
Fair value of warrants outstanding (per warrant) (in Dollars per share)	$14.54	$12.80
Aggregate fair value of warrants outstanding (in Dollars)	$5,623	$5,099
Number of warrants outstanding (in Shares)	386,750	398,250

Note_3_Merger_with_OnCore_Biop2

Note 3 - Merger with OnCore Biopharma, Inc. (“OnCore”) (Details) (USD $)	3 Months Ended	12 Months Ended	0 Months Ended	1 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Mar. 03, 2015	Mar. 31, 2015	Jan. 11, 2015
Note 3 - Merger with OnCore Biopharma, Inc. (“OnCore”) (Details) [Line Items]
Business Combination, Acquisition Related Costs	$9,295,000
Stock Issued During Period, Value, Acquisitions	380,815,000
Fair Value Assumptions, Risk Free Interest Rate	0.49%	1.00%
Fair Value Assumptions, Expected Volatility Rate	98.68%	85.22%
Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Fair Value Assumptions, Expected Term	219 days	6 months
Goodwill	155,865,000			155,865,000
Common Shares Issued without Subjects [Member] | OnCore [Member]
Note 3 - Merger with OnCore Biopharma, Inc. (“OnCore”) (Details) [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)			20,347,906
Business Acquisition, Share Price (in Dollars per share)			$18.26
Common Shares Issued Subject to Repurchase Provision [Member] | OnCore [Member]
Note 3 - Merger with OnCore Biopharma, Inc. (“OnCore”) (Details) [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)			3,625,412
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned			66,196,000
Fair Value Assumptions, Risk Free Interest Rate			0.74%
Fair Value Assumptions, Expected Volatility Rate			81.00%
Fair Value Assumptions, Expected Dividend Rate			0.00%
Fair Value Assumptions, Expected Term			4 years
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned, Attributed as Pre-combination Service and Included as Part of Total Purchase Price			9,262,000
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned, Attributed as Post-combination Compensation Expense			56,934,000
Business Acquisition, Compensation Expense Related to Vesting of Shares				1,205,000
OnCore Stock Options [Member] | OnCore [Member]
Note 3 - Merger with OnCore Biopharma, Inc. (“OnCore”) (Details) [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned			3,287,000
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned, Attributed as Pre-combination Service and Included as Part of Total Purchase Price			1,127,000
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned, Attributed as Post-combination Compensation Expense			2,160,000
Business Acquisition, Compensation Expense Related to Vesting of Shares				44,000
Common Stock, Capital Shares Reserved for Future Issuance (in Shares)			184,332
OnCore [Member]
Note 3 - Merger with OnCore Biopharma, Inc. (“OnCore”) (Details) [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired					100.00%
Stock Issued During Period, Shares, Acquisitions (in Shares)			23,973,315
Stock Issued During Period, Value, Acquisitions			381,942,000
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned			381,942,000
Business Combination, Consideration Transferred			381,942,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			389,652,000
Goodwill			155,865,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual				-1,027,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual				$0

Note_3_Merger_with_OnCore_Biop3

Note 3 - Merger with OnCore Biopharma, Inc. (“OnCore”) (Details) - Business Acquistion Assets and Liabilities Transferred (USD $)	0 Months Ended
	Mar. 03, 2015	Mar. 31, 2015
Business Acquisition [Line Items]
Goodwill		$155,865,000
Shares Issued Without Subjects [Member] | OnCore [Member]
Business Acquisition [Line Items]
Common shares issued	371,553,000
Shares Issued Subject to Repurchase Provision [Member] | OnCore [Member]
Business Acquisition [Line Items]
Common shares issued	9,262,000
Shares Issuable for OnCore Stock Options [Member] | OnCore [Member]
Business Acquisition [Line Items]
Common shares issued	1,127,000
OnCore [Member]
Business Acquisition [Line Items]
Common shares issued	381,942,000
Cash	324,000
Prepaid expenses and other assets	127,000
Accounts receivable	8,000
Property and equipment	147,000
Acquired intangible assets	389,652,000
Goodwill	155,865,000
Accounts payable and accrued liabilities	-3,580,000
Other noncurrent liabilities (note 8)	-4,736,000
Deferred income tax liability	-155,865,000
Total purchase price allocation	$381,942,000

Note_3_Merger_with_OnCore_Biop4

Note 3 - Merger with OnCore Biopharma, Inc. (“OnCore”) (Details) - Pro Forma Financial Information (OnCore [Member], USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
OnCore [Member]
Note 3 - Merger with OnCore Biopharma, Inc. (“OnCore”) (Details) - Pro Forma Financial Information [Line Items]
Gross Revenue	$4,682	$4,430
Loss from operations	-25,071	-10,434
Net loss	($19,054)	($22,483)
Basic and diluted loss per share (in Dollars per share)	($0.41)	($0.51)

Note_4_Collaborations_Contract2

Note 4 - Collaborations, Contracts and Licensing Agreements (Details) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

Jan. 13, 2014

Jun. 21, 2013

Mar. 31, 2015

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Nov. 16, 2014

Dec. 31, 2014

8-May-13

Apr. 22, 2014

Jul. 14, 2010

Oct. 31, 2014

10-May-10

Aug. 09, 2012

Note 4 - Collaborations, Contracts and Licensing Agreements (Details) [Line Items]

Maximum Potential Transaction Value

$86,200,000

Near Term Contract Payments

17,500,000

Licenses Revenue

5,000,000

1,162,000

741,000

Deferred Revenue

13,130,000

15,716,000

Milestone Payment

200,000

3,250,000

Accrued Contract Revenue, Percentage

2.50%

Increase to Support Development Plans [Member] | DoD [Member]

Note 4 - Collaborations, Contracts and Licensing Agreements (Details) [Line Items]

Potential Contract Funding Amount

6,970,000

Increased Funding for Stage One [Member] | DoD [Member]

Note 4 - Collaborations, Contracts and Licensing Agreements (Details) [Line Items]

Potential Contract Funding Amount

2,100,000

Stage One [Member] | DoD [Member]

Note 4 - Collaborations, Contracts and Licensing Agreements (Details) [Line Items]

Potential Contract Funding Amount

43,819,000

Contract Extension [Member] | Maximum [Member]

Note 4 - Collaborations, Contracts and Licensing Agreements (Details) [Line Items]

Potential Contract Funding Amount

140,000,000

Alnylam License Agreement [Member]

Note 4 - Collaborations, Contracts and Licensing Agreements (Details) [Line Items]

Licenses Revenue

150,000

Marqibo [Member]

Note 4 - Collaborations, Contracts and Licensing Agreements (Details) [Line Items]

Royalty Revenue

57,000

46,000

DoD [Member]

Note 4 - Collaborations, Contracts and Licensing Agreements (Details) [Line Items]

Potential Contract Funding Amount

34,700,000

Optional Excercised Contractual Option, Amount

7,000,000

Monsanto [Member]

Note 4 - Collaborations, Contracts and Licensing Agreements (Details) [Line Items]

Approximate Option Period

4 years

Licenses Revenue

842,000

[1]

545,000

[1]

BMS [Member]

Note 4 - Collaborations, Contracts and Licensing Agreements (Details) [Line Items]

Deferred Revenue

3,000,000

Dicerna [Member]

Note 4 - Collaborations, Contracts and Licensing Agreements (Details) [Line Items]

Licenses Revenue

263,000

[2]

[2]

Deferred Revenue

2,500,000

Milestone Payment

22,000,000

Talon Therapeutics [Member]

Note 4 - Collaborations, Contracts and Licensing Agreements (Details) [Line Items]

Potential Contract Funding Amount

$18,000,000

[1]

Option and Services Agreements with Monsanto Company ("Monsanto")On January 13, 2014, the Company and Monsanto signed an Option Agreement and a Services Agreement (together, the "Agreements"). Under the Agreements, Monsanto has an option to obtain a license to use the Company's proprietary delivery technology and related intellectual property for use in agriculture. Over the option period, which is expected to be approximately four years, the Company will provide lipid formulations for Monsanto's research and development activities, and Monsanto will make certain payments to the Company to maintain its option rights. The maximum potential value of the transaction, following the successful completion of milestones, is $86,200,000. From inception of the contract to March 31, 2015, the Company had received $17,500,000 in near term payments as outlined in the terms of the Agreements. The amounts received relate to research services and use of the Company's technology over the option period, and are recognized as revenue on a straight-line basis over the option period.Under the Agreements, the Company has established a wholly-owned subsidiary, PADCo. The Company has determined that PADCo is a variable interest entity ("VIE"); however, Monsanto is the primary beneficiary of the arrangement. PADCo was established to perform research and development activities, which have been funded by Monsanto in return for a call option to acquire the equity or all of the assets of PADCo. At any time during the option period, Monsanto may choose to exercise its option, in which case Monsanto would pay the Company an option exercise fee and would receive a worldwide, exclusive right to use the Company's proprietary delivery technology in the field of agriculture. Monsanto may elect to terminate this option at their discretion. The Company retains all rights to therapeutics uses of all current intellectual property and intellectual property developed under the Agreements. The Company's initial investment is not significant, and has no implied or unfunded commitments and the maximum exposure to loss is limited to the amount of investment in the entity. The Company has included its investment in PADco in Other Assets. There were no significant assets or liabilities for PADCo as at March 31, 2015. There was no equity income or loss with respect to PADCo recorded for the quarter ended March 31, 2015.

[2]

License and Development and Supply Agreement with Dicerna Pharmaceuticals, Inc. ("Dicerna")On November 16, 2014, the Company signed a License Agreement and a Development and Supply Agreement (together, the "Agreements") with Dicerna to develop, manufacture, and commercialize products directed to the treatment of Primary Hyperoxaluria 1 ("PH1"). In consideration for the rights granted under the Agreements, Dicerna paid the Company an upfront cash payment of $2,500,000. The Company is also entitled to receive payments from Dicerna on manufacturing and services provided, as well as further payments with the achievement of development and regulatory milestones of up to $22,000,000, in aggregate, and potential commercial royalties. Further, under the Agreements, a joint development committee has been established to provide guidance and direction on the progression of the collaboration.The Company determined the deliverables under the Agreements included the rights granted, participation in the joint development committee, materials manufactured and other services provided, as directed under the joint development committee. The Company has determined that manufacturing services and other services provided have standalone value, as a separate statement of work is executed and invoiced for each manufacturing or service work order. The relative fair values are determined as a batch price or fee is estimated upon the execution of each work order, with actual expenditures charged at comparable market rates with embedded margins on each work order. Manufacturing work orders are invoiced at the time of execution of the work order, at the initiation of manufacture, and at the release of materials. Revenue from service work orders is recognized as the services are performed. The license and participation in the joint development committee have been determined by the Company to not have standalone value due to the uniqueness of the subject matter under the Agreements. Therefore, these deliverables are treated as one unit of accounting and recognized as revenue over the performance period, which the Company has estimated to be approximately 28 months as at March 31, 2015 (December 31, 2014 - 28 months).The Company believes the development and regulatory milestones are substantive, due to the existence of substantive uncertainty upon the execution of the arrangement, and that the achievement of the development and regulatory events are based, in part, on the Company's performance and the occurrence of a specific outcome resulting from performance. The Company has not received any milestone payments to date.

Note_4_Collaborations_Contract3

Note 4 - Collaborations, Contracts and Licensing Agreements (Details) - Revenue Recognized Under Collaborations, Contracts and Licensing Agreements (USD $)	1 Months Ended	3 Months Ended
	Jun. 21, 2013	Mar. 31, 2015		Mar. 31, 2014
Collaborations and contracts
Contract Revenue		$3,520,000		$3,689,000
Licensing fees, milestone and royalty payments
License Revenue	5,000,000	1,162,000		741,000
Total revenue		4,682,000		4,430,000
DoD [Member]
Collaborations and contracts
Contract Revenue		3,045,000	[1]	3,240,000	[1]
Monsanto [Member]
Collaborations and contracts
Contract Revenue		248,000	[2]	243,000	[2]
Licensing fees, milestone and royalty payments
License Revenue		842,000	[2]	545,000	[2]
BMS [Member]
Collaborations and contracts
Contract Revenue			[3]	206,000	[3]
Dicerna [Member]
Collaborations and contracts
Contract Revenue		227,000	[4]		[4]
Licensing fees, milestone and royalty payments
License Revenue		263,000	[4]		[4]
Acuitas [Member]
Licensing fees, milestone and royalty payments
License Revenue			[5]	150,000	[5]
Spectrum [Member]
Licensing fees, milestone and royalty payments
License Revenue		$57,000	[6]	$46,000	[6]
[1]	Contract with United States Government's Department of Defense ("DoD") to develop TKM-EbolaOn July 14, 2010, the Company signed a contract with the DoD to advance TKM-Ebola, an RNAi therapeutic utilizing the Company's lipid nanoparticle technology to treat Ebola virus infection.In the initial phase of the contract, funded as part of the Transformational Medical Technologies program, the Company was eligible to receive up to $34,700,000. This initial funding is for the development of TKM-Ebola including completion of preclinical development, filing an Investigational New Drug application with the United States Food and Drug Administration ("FDA") and completing a Phase 1 human safety clinical trial. On May 8, 2013, the Company announced that the contract had been modified to support development plans that integrate recent advancements in lipid nanoparticle ("LNP") formulation and manufacturing technologies. The contract modification increased the stage one targeted funding by an additional $6,970,000. On April 22, 2014, the Company and the DoD signed a contract modification to further increase the stage one targeted funding by $2,100,000 to $43,819,000. The additional funding is to compensate the Company for unrecovered overheads related to the temporary stop-work period that occurred in 2012 and to provide additional overhead funding should it be required.The DoD has the option of extending the contract beyond the initial funding period to support the advancement of TKM-Ebola through to the completion of clinical development and FDA approval. Based on the contract's budget this would provide the Company with up to $140,000,000 in funding for the entire program. In October 2014, the Company and the DoD exercised an option to add $7,000,000 for the manufacture of TKM-Ebola-Guinea (the "Ebola-Guinea Amendment"), developed by the Company, targeting the Ebola-Guinea strain responsible for the current outbreak in West Africa.Under the contract, the Company is reimbursed for costs incurred, including an allocation of overhead costs, and is paid an incentive fee. At the beginning of the fiscal year the Company estimates its labour and overhead rates for the year ahead. At the end of the year the actual labour and overhead rates are calculated and revenue is adjusted accordingly. The Company's actual labour and overhead rates will differ from its estimated rates based on actual costs incurred and the proportion of the Company's efforts on contracts and internal products versus indirect activities. Within minimum and maximum collars, the amount of incentive fee the Company can earn under the contract varies based on costs incurred versus budgeted costs. During the contractual period, incentive fee revenue and total costs are impacted by management's estimate and judgments which are continuously reviewed and adjusted as necessary using the cumulative catch-up method. At March 31, 2015, the Company believes it can reliably estimate the final contract costs so has recognized the portion of expected incentive fee which has been earned to date.
[2]	Option and Services Agreements with Monsanto Company ("Monsanto")On January 13, 2014, the Company and Monsanto signed an Option Agreement and a Services Agreement (together, the "Agreements"). Under the Agreements, Monsanto has an option to obtain a license to use the Company's proprietary delivery technology and related intellectual property for use in agriculture. Over the option period, which is expected to be approximately four years, the Company will provide lipid formulations for Monsanto's research and development activities, and Monsanto will make certain payments to the Company to maintain its option rights. The maximum potential value of the transaction, following the successful completion of milestones, is $86,200,000. From inception of the contract to March 31, 2015, the Company had received $17,500,000 in near term payments as outlined in the terms of the Agreements. The amounts received relate to research services and use of the Company's technology over the option period, and are recognized as revenue on a straight-line basis over the option period.Under the Agreements, the Company has established a wholly-owned subsidiary, PADCo. The Company has determined that PADCo is a variable interest entity ("VIE"); however, Monsanto is the primary beneficiary of the arrangement. PADCo was established to perform research and development activities, which have been funded by Monsanto in return for a call option to acquire the equity or all of the assets of PADCo. At any time during the option period, Monsanto may choose to exercise its option, in which case Monsanto would pay the Company an option exercise fee and would receive a worldwide, exclusive right to use the Company's proprietary delivery technology in the field of agriculture. Monsanto may elect to terminate this option at their discretion. The Company retains all rights to therapeutics uses of all current intellectual property and intellectual property developed under the Agreements. The Company's initial investment is not significant, and has no implied or unfunded commitments and the maximum exposure to loss is limited to the amount of investment in the entity. The Company has included its investment in PADco in Other Assets. There were no significant assets or liabilities for PADCo as at March 31, 2015. There was no equity income or loss with respect to PADCo recorded for the quarter ended March 31, 2015.
[3]	Bristol-Myers Squibb ("BMS") collaborationOn May 10, 2010 the Company announced the expansion of its research collaboration with BMS. Under the new agreement, BMS uses small interfering RNA ("siRNA") molecules formulated by the Company in LNP technology to silence target genes of interest. BMS is conducting the preclinical work to validate the function of certain genes and share the data with the Company. The Company could use the preclinical data to develop RNAi therapeutic drugs against the therapeutic targets of interest. The Company received $3,000,000 from BMS concurrent with the signing of the agreement and recorded the amount as deferred revenue. The Company was required to provide a pre-determined number of LNP batches over the four-year agreement. BMS had a first right to negotiate a licensing agreement on certain RNAi products developed by the Company that evolve from BMS validated gene targets.Revenue from the May 10, 2010 agreement with BMS was being recognized as the Company produces the related LNP batches.The revenue earned for the three months ended March 31, 2014 was related to BMS batches shipped during the period. In August 2014, the agreement expired and both companies' obligations under the agreement ended.
[4]	License and Development and Supply Agreement with Dicerna Pharmaceuticals, Inc. ("Dicerna")On November 16, 2014, the Company signed a License Agreement and a Development and Supply Agreement (together, the "Agreements") with Dicerna to develop, manufacture, and commercialize products directed to the treatment of Primary Hyperoxaluria 1 ("PH1"). In consideration for the rights granted under the Agreements, Dicerna paid the Company an upfront cash payment of $2,500,000. The Company is also entitled to receive payments from Dicerna on manufacturing and services provided, as well as further payments with the achievement of development and regulatory milestones of up to $22,000,000, in aggregate, and potential commercial royalties. Further, under the Agreements, a joint development committee has been established to provide guidance and direction on the progression of the collaboration.The Company determined the deliverables under the Agreements included the rights granted, participation in the joint development committee, materials manufactured and other services provided, as directed under the joint development committee. The Company has determined that manufacturing services and other services provided have standalone value, as a separate statement of work is executed and invoiced for each manufacturing or service work order. The relative fair values are determined as a batch price or fee is estimated upon the execution of each work order, with actual expenditures charged at comparable market rates with embedded margins on each work order. Manufacturing work orders are invoiced at the time of execution of the work order, at the initiation of manufacture, and at the release of materials. Revenue from service work orders is recognized as the services are performed. The license and participation in the joint development committee have been determined by the Company to not have standalone value due to the uniqueness of the subject matter under the Agreements. Therefore, these deliverables are treated as one unit of accounting and recognized as revenue over the performance period, which the Company has estimated to be approximately 28 months as at March 31, 2015 (December 31, 2014 - 28 months).The Company believes the development and regulatory milestones are substantive, due to the existence of substantive uncertainty upon the execution of the arrangement, and that the achievement of the development and regulatory events are based, in part, on the Company's performance and the occurrence of a specific outcome resulting from performance. The Company has not received any milestone payments to date.
[5]	License and collaboration with Alnylam Pharmaceuticals, Inc. ("Alnylam") and Acuitas Therapeutics Inc. ("Acuitas", formerly AlCana Technologies Inc.)Milestone receipts and paymentsIn the three months ended March 31, 2014, the Company earned a $150,000 milestone from Acuitas, subsequent to Acuitas receiving a milestone payment from Alnylam with respect to Alnylam initiating a Phase III trial for ALN-TTR02.Arbitration with Alnylam and Ascletis Pharmaceuticals (Hangzhou) Co. Ltd. ("Ascletis")On June 21, 2013, the Company transferred manufacturing process technology to Ascletis to enable them to produce ALN-VSP, a product candidate licensed to them by Alnylam. The Company believes that under the new licensing agreement with Alnylam, the technology transfer to Ascletis triggers a $5,000,000 milestone obligation from Alnylam to the Company. However, Alnylam has demanded a declaration that the Company has not yet met its milestone obligations. The Company disputes Alnylam's position. To remedy this dispute, the Company and Alnylam have commenced arbitration proceedings as provided for under the agreement. The hearing date for this arbitration is currently set for the second week in May 2015. The Company has not recorded any revenue in respect of this milestone.
[6]	Agreements with Spectrum Pharmaceuticals, Inc. ("Spectrum")On May 6, 2006, the Company signed a number of agreements with Talon Therapeutics, Inc. ("Talon", formerly Hana Biosciences, Inc.) including the grant of worldwide licenses (the "Talon License Agreement") for three of the Company's chemotherapy products, Marqibo, AlocrestTM (Optisomal Vinorelbine) and BrakivaTM (Optisomal Topotecan).On August 9, 2012, the Company announced that Talon had received accelerated approval for Marqibo from the FDA for the treatment of adult patients with Philadelphia chromosome negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Marqibo is a liposomal formulation of the chemotherapy drug vincristine. There are no further milestones related to Marqibo but the Company is eligible to receive total milestone payments of up to $18,000,000 on Alocrest and Brakiva.Talon was acquired by Spectrum in July 2013. The acquisition does not affect the terms of the license between Talon and the Company. On September 3, 2013, Spectrum announced that they had shipped the first commercial orders of Marqibo. For the three months ended March 31, 2015, the Company recorded $57,000 in Marqibo royalty revenue (three months ended March 31, 2014 - $46,000). For the three months ended March 31, 2015, the Company accrued 2.5% in royalties due to TPC in respect of the Marqibo royalty earned by the Company - see note 8, contingencies and commitments.

Note_4_Collaborations_Contract4

Note 4 - Collaborations, Contracts and Licensing Agreements (Details) - Deferred Collaborations and Contracts Revenue (USD $)	Mar. 31, 2015		Dec. 31, 2014		Nov. 16, 2014
Deferred Revenue Arrangement [Line Items]
Deferred Revenue Current Portion	$5,233,000		$5,779,000
Deferred Revenue Noncurrent Portion	7,897,000		9,937,000
Total deferred revenue	13,130,000		15,716,000
DoD [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue Current Portion	222,000	[1]	313,000	[1]
Monsanto [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue Current Portion	3,888,000	[2]	4,245,000	[2]
Deferred Revenue Noncurrent Portion	6,965,000	[2]	8,666,000	[2]
Dicerna [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue Current Portion	1,123,000	[3]	1,221,000	[3]
Deferred Revenue Noncurrent Portion	932,000	[3]	1,271,000	[3]
Total deferred revenue					$2,500,000
[1]	Contract with United States Government's Department of Defense ("DoD") to develop TKM-EbolaOn July 14, 2010, the Company signed a contract with the DoD to advance TKM-Ebola, an RNAi therapeutic utilizing the Company's lipid nanoparticle technology to treat Ebola virus infection.In the initial phase of the contract, funded as part of the Transformational Medical Technologies program, the Company was eligible to receive up to $34,700,000. This initial funding is for the development of TKM-Ebola including completion of preclinical development, filing an Investigational New Drug application with the United States Food and Drug Administration ("FDA") and completing a Phase 1 human safety clinical trial. On May 8, 2013, the Company announced that the contract had been modified to support development plans that integrate recent advancements in lipid nanoparticle ("LNP") formulation and manufacturing technologies. The contract modification increased the stage one targeted funding by an additional $6,970,000. On April 22, 2014, the Company and the DoD signed a contract modification to further increase the stage one targeted funding by $2,100,000 to $43,819,000. The additional funding is to compensate the Company for unrecovered overheads related to the temporary stop-work period that occurred in 2012 and to provide additional overhead funding should it be required.The DoD has the option of extending the contract beyond the initial funding period to support the advancement of TKM-Ebola through to the completion of clinical development and FDA approval. Based on the contract's budget this would provide the Company with up to $140,000,000 in funding for the entire program. In October 2014, the Company and the DoD exercised an option to add $7,000,000 for the manufacture of TKM-Ebola-Guinea (the "Ebola-Guinea Amendment"), developed by the Company, targeting the Ebola-Guinea strain responsible for the current outbreak in West Africa.Under the contract, the Company is reimbursed for costs incurred, including an allocation of overhead costs, and is paid an incentive fee. At the beginning of the fiscal year the Company estimates its labour and overhead rates for the year ahead. At the end of the year the actual labour and overhead rates are calculated and revenue is adjusted accordingly. The Company's actual labour and overhead rates will differ from its estimated rates based on actual costs incurred and the proportion of the Company's efforts on contracts and internal products versus indirect activities. Within minimum and maximum collars, the amount of incentive fee the Company can earn under the contract varies based on costs incurred versus budgeted costs. During the contractual period, incentive fee revenue and total costs are impacted by management's estimate and judgments which are continuously reviewed and adjusted as necessary using the cumulative catch-up method. At March 31, 2015, the Company believes it can reliably estimate the final contract costs so has recognized the portion of expected incentive fee which has been earned to date.
[2]	Option and Services Agreements with Monsanto Company ("Monsanto")On January 13, 2014, the Company and Monsanto signed an Option Agreement and a Services Agreement (together, the "Agreements"). Under the Agreements, Monsanto has an option to obtain a license to use the Company's proprietary delivery technology and related intellectual property for use in agriculture. Over the option period, which is expected to be approximately four years, the Company will provide lipid formulations for Monsanto's research and development activities, and Monsanto will make certain payments to the Company to maintain its option rights. The maximum potential value of the transaction, following the successful completion of milestones, is $86,200,000. From inception of the contract to March 31, 2015, the Company had received $17,500,000 in near term payments as outlined in the terms of the Agreements. The amounts received relate to research services and use of the Company's technology over the option period, and are recognized as revenue on a straight-line basis over the option period.Under the Agreements, the Company has established a wholly-owned subsidiary, PADCo. The Company has determined that PADCo is a variable interest entity ("VIE"); however, Monsanto is the primary beneficiary of the arrangement. PADCo was established to perform research and development activities, which have been funded by Monsanto in return for a call option to acquire the equity or all of the assets of PADCo. At any time during the option period, Monsanto may choose to exercise its option, in which case Monsanto would pay the Company an option exercise fee and would receive a worldwide, exclusive right to use the Company's proprietary delivery technology in the field of agriculture. Monsanto may elect to terminate this option at their discretion. The Company retains all rights to therapeutics uses of all current intellectual property and intellectual property developed under the Agreements. The Company's initial investment is not significant, and has no implied or unfunded commitments and the maximum exposure to loss is limited to the amount of investment in the entity. The Company has included its investment in PADco in Other Assets. There were no significant assets or liabilities for PADCo as at March 31, 2015. There was no equity income or loss with respect to PADCo recorded for the quarter ended March 31, 2015.
[3]	License and Development and Supply Agreement with Dicerna Pharmaceuticals, Inc. ("Dicerna")On November 16, 2014, the Company signed a License Agreement and a Development and Supply Agreement (together, the "Agreements") with Dicerna to develop, manufacture, and commercialize products directed to the treatment of Primary Hyperoxaluria 1 ("PH1"). In consideration for the rights granted under the Agreements, Dicerna paid the Company an upfront cash payment of $2,500,000. The Company is also entitled to receive payments from Dicerna on manufacturing and services provided, as well as further payments with the achievement of development and regulatory milestones of up to $22,000,000, in aggregate, and potential commercial royalties. Further, under the Agreements, a joint development committee has been established to provide guidance and direction on the progression of the collaboration.The Company determined the deliverables under the Agreements included the rights granted, participation in the joint development committee, materials manufactured and other services provided, as directed under the joint development committee. The Company has determined that manufacturing services and other services provided have standalone value, as a separate statement of work is executed and invoiced for each manufacturing or service work order. The relative fair values are determined as a batch price or fee is estimated upon the execution of each work order, with actual expenditures charged at comparable market rates with embedded margins on each work order. Manufacturing work orders are invoiced at the time of execution of the work order, at the initiation of manufacture, and at the release of materials. Revenue from service work orders is recognized as the services are performed. The license and participation in the joint development committee have been determined by the Company to not have standalone value due to the uniqueness of the subject matter under the Agreements. Therefore, these deliverables are treated as one unit of accounting and recognized as revenue over the performance period, which the Company has estimated to be approximately 28 months as at March 31, 2015 (December 31, 2014 - 28 months).The Company believes the development and regulatory milestones are substantive, due to the existence of substantive uncertainty upon the execution of the arrangement, and that the achievement of the development and regulatory events are based, in part, on the Company's performance and the occurrence of a specific outcome resulting from performance. The Company has not received any milestone payments to date.

Note_5_Accounts_Payable_and_Ac2

Note 5 - Accounts Payable and Accrued Liabilities (Details) - Accounts Payable and Accrued Liabilities (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Accounts Payable and Accrued Liabilities [Abstract]
Trade accounts payable	$7,242	$2,044
Research and development accruals	3,417	2,391
License fee accruals		250
Professional fee accruals	1,746	1,294
Deferred lease inducements	335	250
Payroll accruals	28	2,873
Other accrued liabilities	1,251	226
	$14,019	$9,328

Note_6_Financing_Details

Note 6 - Financing (Details) (USD $)	1 Months Ended	3 Months Ended
	Mar. 25, 2015	Mar. 31, 2015	Mar. 31, 2014
Note 6 - Financing (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)	7,500,000
Share Price (in Dollars per share)	$20.25
Proceeds from Issuance of Common Stock	$151,875,000	$142,175,000	$56,477,000
Number of Additional Shares Authorized (in Shares)	1,125,000
Potential Proceeds of Additional Shares Authorized	22,781,000
Payments of Stock Issuance Costs	9,700,000
Net of Stock Issuance Costs [Member]
Note 6 - Financing (Details) [Line Items]
Proceeds From Issuance Of Common Stock Net	$142,175,000

Note_7_Concentrations_of_Credi1

Note 7 - Concentrations of Credit Risk (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Risks and Uncertainties [Abstract]
Accounts Receivable, Net	$4,564,000	$1,903,000

Note_8_Contingencies_and_Commi1

Note 8 - Contingencies and Commitments (Details)

1 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

Mar. 31, 2004

Mar. 31, 2004

Mar. 31, 2015

Mar. 31, 2015

Dec. 31, 2013

Dec. 31, 2012

Jan. 16, 2015

Mar. 31, 2015

Mar. 31, 2014

Mar. 31, 2015

Dec. 31, 2014

Oct. 31, 2014

Nov. 30, 2014

Feb. 28, 2014

Oct. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 30, 2014

Dec. 31, 2012

Dec. 31, 2014

USD ($)

CAD

USD ($)

CAD

USD ($)

USD ($)

Subsequent Event [Member]

Marqibo [Member]

Marqibo [Member]

Marqibo [Member]

Marqibo [Member]

Enantigen [Member]

OnCore [Member]

OnCore [Member]

OnCore [Member]

OnCore [Member]

OnCore [Member]

OnCore [Member]

Up-front Payment Arrangement [Member]

Arcturus [Member]

Arbitration with the University of British Columbia [Member]

USD ($)

USD ($)

CAD

USD ($)

OnCore [Member]

Drexel and Blumberg [Member]

Drexel and Blumberg [Member]

Blumberg [Member]

NeuroVive [Member]

NeuroVive [Member]

Cytos [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

CAD

USD ($)

USD ($)

Note 8 - Contingencies and Commitments (Details) [Line Items]

Percent of Costs Funded by TPC

27.00%

27.00%

Maximum Contribution for Product

$7,179,000

9,323,000

Cumulative Contribution for Product

2,923,000

3,702,000

Royalty Guarantees Commitments Percentage

2.50%

2.50%

Royalty Revenue

57,000

46,000

Royalty Payable

1,000

1,000

Royalties Paid or Accrued

1,000

Contractual Obligation

2,916,000

3,694,000

Upfront Fee

300,000

Milestone Payment

200,000

3,250,000

250,000

Loss Contingency, Damages Sought, Value

3,500,000

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

21,000,000

Business Combination, Contingent Consideration, Liability

4,736,000

4,736,000

Regulatory Milestone Payments, Discount Rate

17.70%

License Costs

50,000

150,000

1,000,000

License Agreement, Maximum Development and Regulatory Milestone Payments per License

1,000,000

3,500,000

47,000,000

67,000,000

License Agreement, Maximum Sales Performance Milestone Payments per License

92,500,000

102,500,000

110,000,000

Contractual Obligation, Amount of Research Funding per Year

1,000,000

Research Funding Agreement, Right to Obtain Exclusive License, Upfront Payment

100,000

Research Funding Agreement, Right to Obtain Exclusive License, Maximum Development and Regulatory Milestone Payments

8,100,000

Research Funding Agreement, Right to Obtain Exclusive License, Maximum Commercialization Milestone Payments

92,500,000

License Agreement, Early Termination Fee

$2,000,000